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clinicaltrials.gov/ct2/results/map?cond=Multiple+Sclerosis&map, dated Nov.22.2018
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History & Review on M.S
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■ The first one on 1940s.
■ Jean-Martin Charcot
■ The first drug was used: Cortisol
■ disease-modifying therapies (DMTs)
■ Affects young to middle- aged adults
■ Women affected more than men
https://fa.wikipedia.org/wiki
dated on Dec.5.2018
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DRAFT SLIDESPrevalence :
https://www.researchgate.net/publication/40025561_Multiple_sclerosis_Geoepidemiology, dated on Jan.1.2019
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■ Myelin sheath
■ Segmented lamination that wraps axons of many nerve cells
■ Increases velocity of nerve impulse conduction in the axons
■ Composed of myelin, a substance with high lipid content 
■ Characterized by chronic inflammation, demyelination, and gliosis
(scarring) in the CNS
■ Subsequent antigen-antibody reaction leads to demyelination of axons
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https://fa.wikipedia.org/wiki, dated on Dec. 5. 2018
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Disease activity persists: 
brain atrophy is accelerated
Figure reproduced with permission from Oxford PharmaGenesis from Giovannoni G et al. Brain health: time matters in multiple sclerosis.
© 2015 Oxford PharmaGenesis Ltd. Available at: www.msbrainhealth.org
This example illustrates how brain atrophy may be accelerated in a person with untreated MS, 
with disease onset at 25 years of age, compared with a healthy individual 
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■ Clinically Isolated Syndrome (CIS)
1. shows characteristics of inflammatory demyelination 
■ Relapsing-Remitting Multiple Sclerosis (RRMS)
1. with progressive worsening of nerve functions with each attack
2. Accounts for 85% of MS patients
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https://my-ms.org/ms_types.htm/dated on Dec. 5.2018
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■ Secondary Progressive Multiple Sclerosis  (SPMS)
1. Initial period of relapsing-remitting, then steady worsening of disease
2. 50% of patients diagnosed with RRMS develop into this variety within 10 yrs
without drug treatment
■ Primary-Progressive Multiple Sclerosis (PPMS)
1. characterized by worsening neurologic function
2. Slow continuous worsening of disease from onset
3. Only about 10%
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https://my-ms.org/ms_types.htm/ dated on De. 5.2018
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CNS, central nervous system; MRI, magnetic resonance imaging; RRMS, relapsing–remitting multiple sclerosis
1. Barkhof F et al., 1992; 2. Kappos L et al., 1999
Figure adapted with permission from Oxford PharmaGenesis from Giovannoni G et al. Brain health: time matters in multiple sclerosis. © 2015 Oxford 
PharmaGenesis Ltd. Available at: www.msbrainhealth.org
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https://www.google.com/search?q=multiple+sclerosis dated on Dec.9.2018
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The circus plot summarizes all the known MS-associated risk loci. https://www.ncbi.nlm.nih.gov/books/NBK470155, Dated on Dec. 25.2018
Genetic atlas of multiple sclerosis
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 in  MS:
Microglia activated & polarized + Produce of toxic factors
Oligodendrocyte damage 
***
In addition, the phagocytotic function of microglia would directly cause 
oligodendrocyte loss
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Genetic
Predisposition
Environmental
Trigger
Immune-mediated Attack
Loss of Myelin
& Nerve Fiber
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Potential PPARγ agonists treatment approach in demyelination
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Elevated Levels of Proinflammatory Cytokines
(Methods)
Mean age 38 ± 2.8 
Gender (F/M) 15/5 
Ms. diagnosis: Remitting 16
Primary, progressing 1, Secondary 
progressing 3
Treatment: MDT: 5,  IFNβ: 6,
Glatiramer acetate: 2,  None: 7
 cytokines analyzed
■ IL-2RA, CCL5, CCL11, CXCL1, 
CXCL10, CXCL12, MIF, IFNγ
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■ CD8+ and Th1 lymphocytes playing a central role in MS brain 
pathology
■ increased levels of IFNγ were found together with CCL5
■ a strong connection between these cytokines, with IFNγ central to 
activating CCL5
■ the CCL5 interaction with CCL27
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DRAFT SLIDESNormal Function of the Gut Microbiota
■ Lactic acid bacteria can produce 
vitamin B12.
■ Biﬁdobacteria are the main 
producers for folate, which is 
involved in DNA synthesis and 
DNA repair.
■ Normal ﬂora can systemically and 
locally stimulate the development
of innate and adaptive immune
systems
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The role of the gut microbiota in health and MS
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OLIGOCLONAL IgG BANDS (OCB) IN THE
PATHOLOGY OF MS
IgGs are produced by the immune system to fight infection
Cross the blood brain barrier
Attack the myelin sheath
Inflammation of the CNS
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Nutrition is : a possible factor in the 
pathogenesis of the neurological 
disease multiple sclerosis (MS). 
Nutrition intervention studies suggest 
that diet may be considered as a 
complementary treatment to control 
the progression of the disease.
vitamin D deficiency in serum is a 
risk factor for MS and therefore a 
potential biomarker of MS
Vitamin B-12 has roles in CNS 
function (the methionine synthase–
mediated conversion of homocysteine 
to methionine) which is essential for
DNA and RNA synthesis
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■ MS is a clinical diagnosis:
 Signs and symptoms (cognitive impairment) 
 Medical history
 Laboratory tests 
■ Requires “dissemination in time and space”:
 Space: Evidence of scarring (plaques) in at least two separate areas of 
the CNS
 Time: Evidence that the plaques occurred at different points in time 
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■ Magnetic resonance imaging (MRI)
■ Visual evoked potentials (VEP)
■ Lumbar puncture
■ Nano diagnostic neuro imaging
■ Biomarkers          Osteopontin (OPN)
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DRAFT SLIDESFunction of OPN:
 bone remodeling
wound healing
cancer biology
vascular disorders
 inflammatory diseases 
Expressed in immune cells
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https://en.wikipedia.org/wiki/Osteopontin dated on Dec. 12. 2018
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■ Non Molecular:
 Drugs or Disease Modifying Drugs (DMD)
 Nano Medicines 
 Stem-cell Therapy
 Trans-Differentiation
 Immunotherapy
 Worm Therapy 
 Zinc Aspartate  & IVIGs
■ Molecular :
 DNA Aptamer 
 CD49d antisense
 MicroRNAs
 Gene Therapy 
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Table 1: List of FDA approved drugs// S. Ojha, B. Kumar / Journal of Cellular Immunotherapy dated on 2018
Mechanism of actionDosage and Route
of Administration
Brand nameDrug 
Suppresses expression of
inflammatory cytokines,
Down regulation of
costimulatory molecules 
like
CD 80, CD 40 om Antigen
presenting cells, inhibits T
cell activation
250 mg, SC, every other 
day
Interferon b-1b Betaseron,Interferon b-1b Betaseron,
Same as interferon b-1b30 mg, IM, once a weekInterferon b-1a AvonexInterferon b-1a Avonex
Oldest 
Newest
Depletes B-cells, T- cells,
monocytes, macrophages
and dendritic cells.
IV infusion for 5 
consecutive days,
than for 3 consecutive days 
1 year later 
LemtradaAlemtuzumab
Same as interferon b-1b125 mg, SQ, once every two 
weeks
PlegridyPeg interferon b-1a
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Therapeutic Monoclonal Antibodies
 CD20 antibodies To target B-cells
 Rituximab, Orelizumab, Ofatumumab, Declizumab Cytokine/IL-2 receptor (CD25)
 Alemtuzumab Anti-CD52 monoclonal antibody
 Natalizumab Anti-α4 integrin antibody
Immune modulators 
 IFN/IFN + statins, Teriflunomide Inhibits proliferation of activated T- and B-cells
 Mitoxantrone, Dimethyl fumarate NF-κB inhibition and inhibition of pro-inflammatory cytokines
 Glatiramer acetate, Fingolimod Inhibits release of lymphocytes from lymphoid tissues induction of 
miRNAs
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Cladribine:
• An Adenosine analogue
• Enter cells via specific nucleoside transporter proteins
• as a prodrug
• its activity is dependent on the intracellular accumulation of its active
triphosphate
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The accumulation of active Cladribine (2-CdATP) is dependent on the ratio of deoxycytidine kinase 
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Nano-medicines 
Summary of recent patents against MS
 Yechezkel Barenholz et al. (2008)
 Josbert Maarten Metselaar et al. (2010)
 Sergey Sergeevich Avtushenko et al. 
(2011)
 Yechezkel Barenholz et al. (2015)
Pharmaceutical Liposomal formulation
non charged vesicle forming lipids
derivatised with polyethylene glycol
tetramannosyl-3-L-lysinedioleoyl
glycerol & 2, 3-dipalmitoyl-glycerol-
1-phosphatydyl choline, and also includes 
some oligopeptides
Orglucocorticoid derivative
which is encapsulated in a liposome
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Stem cells and their mode of function and potential
in therapy
Mode of Function/Signalling PathwaysStem Cell Type
Modulation of the immune system
Inhibition of T-cells, B-cells and NK cells
Mesenchymal stem cells
NF-κB
STAT
Hematopoietic stem cells
Replacement therapyNeural stem cells
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 By targeting the lymphatic vessels surrounding the brain, the researchers were 
able to impede the development of MS in a mouse model using a number of 
strategies to block or destroy the vessels, effectively decreasing the amount of 
destructive immune cells capable of causing paralysis.
 During inflammation, they did not change in size or complexity much, but what 
was really exciting to discover they allowed whole immune cells to traffic through 
them.
Blocking the cells in mice seemed to be beneficial…
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■ Results:
Inﬂuence of Preventive 
and Therapeutic 
Application of IVIG
Eﬀects of Therapeutic 
Application of IVIG, 
Zinc Aspartate
the Combination of 
Both
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Eﬀect of therapeutic application of IVIG, zinc aspartate, and the combination of both on formation of inﬂammatory lesions in the CNS of EAE mice
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The monoclonal antibody Natalizumab targets the adhesion molecule very 
late antigen 4 (VLA-4)*
Interfere with the transmigration of leukocytes into the CNS
so
Reduces brain lesions
*VLA-4 = has a role in the maturation, apoptosis, activation, adhesion, and migration of B and T cells
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ATL1102    second-generation antisense oligonucleotide to CD49d RNA**
binds CD49d RNA by Watson-Crick base pairing
reduces CD49d RNA and VLA-4 expression
***
Reduction in the number of CD19, B cells with of VLA-4 expression 
**CD49d RNA = the a chain of VLA-4. 
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 VLA-4, has a role in the maturation, apoptosis, activation, adhesion, 
and migration of B and T cells.
Cumulative number of new active lesions, which is treated with ATL 1102 (this picture is gotten from  https://www.ncbi.nlm.nih.gov/pubmed dated on Dec. 8. 2018)
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■ MicroRNAs (miRNAs): 
miR-21, miR-142-3p, miR-146a, miR-146b, miR-155 & miR-326 
miR-15a, miR-15b, miR-181c & miR-328
As diagnostic 
markers & 
therapeutic targets:  
miR-326, miR-155
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Estimation of number of publications about studies on miRNAs in MS yearly from 2009 to 2018. Based on the retrieved 
papers from the PUBMED database after searching related references by means of miRNA, multiple and sclerosis key 
words, the number of publications about the studies on miRNAs in MS were calculated.
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International journal of  Medical science, 2014; 11(8): 810-818  , dated on  Dec. 10. 2018
miR-155 was up-regulated 
among PBMC, brain and 
blood/plasma
miR-181c and miR-328 
were down-regulated in 
both brain and 
blood/plasma. 
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miRNAs as MS Therapeutic Targets:
 Suppression of miR-155 expression the development of Th1 and Th17 cells.
 miR-326 expression increased significantly in active MS lesions.
 miR-23b expression          IL-17 ,TNF-α, TGF-β.
 miR-124 expression increased in the demyelinated brain 
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Mechanism of action of dysregulated miRNAs in patients with MS
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https://www.ncbi.nlm.nih.gov/pubmed/28943274
■ Abnormalities in the frequency or suppressive, CD4+CD25+FOXP3+ Tregs cause 
various autoimmune diseases:
 engineered an AAV8 vector to contain the full coding sequence (CDS) of the neuroprotein MOG
 placed it under control of a liver-specific promoter
 By day 30, mice that received AAV8.MOG immunotherapy had a significantly greater reduction 
in clinical scores compared to control mice
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■ Demyelinated astrocyte Oligodendrocyte Precursor into CNS:
1. Injection GFP 
2. Injection GFP + Sox2 
Astrocyte differentiation( specially at the time of destruction of Myelin) to     
Oligodendrocyte Precursor & Mature oligodendrocyte
Sox2
Astrocyte
oligodendrocyte 
Precursor
21 Days 
Oligodendrocyte 
Precursor in 
favor of Mature 
oligodendrocyte
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■ During the progressive phase: the microglial cells in the brain  responsible for the 
neurological deterioration
■ microglial cells react when faced with any damage or infection in it
is in principle beneficial
but
becomes harmful when it is prolonged over time
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Receptor P2X4 present in the microglial cells
encourage the body's own repair responses
improve the symptoms during the chronic phase of the disease
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Maximize lifelong 
brain health
1. Minimize delays in diagnosis & 
treatment
2. Monitor disease activity & treat 
to a target
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